Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second‐line chemotherapy

BACKGROUND: Three vascular endothelial growth factor (VEGF) inhibitors, Bevacizumab (BEV), ramucirumab (RAM), and aflibercept (AFL), are widely used for metastatic colorectal cancer (mCRC) patients who are treated with second‐line chemotherapy. The difference in outcome between the three drugs has n...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancer Med
Hlavní autoři: Osumi, Hiroki, Shinozaki, Eiji, Ooki, Akira, Wakatsuki, Takeru, Kamiimabeppu, Daisaku, Sato, Taro, Nakayama, Izuma, Ogura, Mariko, Takahari, Daisuke, Chin, Keisho, Yamaguchi, Kensei
Médium: Artigo
Jazyk:Inglês
Vydáno: John Wiley and Sons Inc. 2020
Témata:
Clinical Cancer Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7877370/
https://ncbi.nlm.nih.gov/pubmed/33347731
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3638
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky